Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2021 and annual treatment report for 2016
Journal of Obstetrics and Gynaecology Research · 2025-01 · 51 (1)
DOI: 10.1111/jog.16168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 25.11.2024. Verfasst von Hiroaki Kajiyama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Gynecology. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Aim
To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2021 and the Annual Treatment Report for 2016, on the outcomes of patients who started treatment in 2016.
Methods
The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2021 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial, and ovarian cancer in 2016 was analyzed by using the Kaplan–Meier, log‐rank, and Wilcoxson tests.
Results
Treatment was initiated in 2021 for 8006 patients with cervical cancer, 13 912 with endometrial cancer, 8337 with ovarian, tubal, and peritoneal cancer, 2375 with ovarian borderline tumors, and with the others (226 vulvar cancer, 161 vaginal cancer, 437 uterine sarcoma, 47 uterine adenosarcoma, 160 trophoblastic diseases). This clinicopathological information was summarized as the Patient Annual Report. The 5‐year survival rates of the patients with cervical cancer were 92.3%, 77.0%, 56.1%, and 30.3% for stages I, II, III, and IV, respectively. The 5‐year survival rates for the patients with endometrial cancer were 94.1%, 88.8%, 71.2%, and 24.5% for stages I, II, III, and IV, respectively. The 5‐year survival rates for the patients with ovarian cancer (surface epithelial‐stromal tumors) were 91.3%, 78.8%, 54.3%, and 36.8% for stages I, II, III, and IV, respectively.
Conclusion
The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Information Science, Iwate Medical University, Yahaba, Japan.
- Department of Obstetrics and Gynecology, Nihon University School of Medicine, Tokyo, Japan.
ORCID-Profile: Hiroaki Kajiyama, Satoshi Tamauchi
Zitieren
APA
Kajiyama, H., Tamauchi, S., Takahashi, F., Kawana, K., & Board members of the 2023 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology (2025). Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2021 and annual treatment report for 2016. Journal of Obstetrics and Gynaecology Research, 51(1). https://doi.org/10.1111/jog.16168
Vancouver
Kajiyama H, Tamauchi S, Takahashi F, Kawana K, Board members of the 2023 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2021 and annual treatment report for 2016. Journal of Obstetrics and Gynaecology Research. 2025;51(1). doi:10.1111/jog.16168
BibTeX
@article{Kajiyama2025,
author = {Kajiyama, Hiroaki and Tamauchi, Satoshi and Takahashi, Fumiaki and Kawana, Kei and Board members of the 2023 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology, Board members of the 2023 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology},
title = {Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2021 and annual treatment report for 2016},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
volume = {51},
number = {1},
doi = {10.1111/jog.16168}
}
EUVIMED